Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian WES/WGS Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentPresbyterian Health PlanPolicy 7.12

    Genetic Testing: Standard Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 7.12 alerts

    Get alerted when Policy 7.12 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for standard WES, WGS, prenatal WES/WGS, and reanalysis of previously uninformative sequencing data for eligible Medicare, Medicaid, and commercial members, subject to the member’s benefit plan and Schedule of Benefits.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Standard Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)
    Policy CodePolicy 7.12
    Change TypeAnnual review with material coverage updates
    Effective DateN/A
    Last ReviewMay 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for WES/WGS through Pres Online.
    SourceLink
    POLICY UPDATE CHANGES

    WGS was added and references were expanded from WES to WES/WGS.

    Eligibility was expanded through age 21, epilepsy coverage was broadened, and prenatal WES/WGS criteria were added.

    WGS codes 81425, 81426, and 81427 were added.

    Epilepsy eligibility requirements were clarified.

    A new eligibility pathway requiring at least two specified features was added.

    RequiredPrior authorization
    <21

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Primary age pathway
    2+Congenital anomaly systems
    2 of 7Alternative features
    6Genetic testing codes
    3Prenatal pathways

    Coverage Criteria

    Pediatric or Adolescent Diagnostic WES/WGS

    WES or WGS is medically necessary for an individual diagnosed before age 21 when all applicable provider and documentation requirements are met and either one qualifying condition from A–D or at least two qualifying conditions from E are present.

    ALL of the following

    • The individual was diagnosed before age 21.
    • ONE of the following qualifying pathways

      • Multiple congenital anomalies involving two or more organ systems.
      • Ongoing developmental regression, defined as unexplained, persistent loss of developmental milestones.
      • Intellectual or developmental disability

        • Intellectual disability with impaired intellectual function more than 2 standard deviations below the mean on standard cognitive assessment and impaired adaptive function.
        • Developmental disability with impaired intellectual or physical function impacting adaptive skills.
      • Epilepsy pathway—ALL of the following

        • Documented history of at least two unprovoked seizures occurring more than 24 hours apart.
        • Epilepsy has an unexplained etiology; seizures cannot be attributed to a structural, metabolic, infectious, immunologic, or other acquired cause, based on history, physical examination, neuroimaging, and other standard clinical evaluations.
        • Epilepsy-specific multigene panel testing inclusive of at least 20 genes has not previously been performed, or was performed but did not identify a pathogenic or likely pathogenic variant sufficient to explain the epilepsy.
        • Previous WES or WGS testing has not been completed.
      • At least TWO of the following

        • Bilateral sensorineural hearing loss of unknown etiology.
        • Symptoms of a complex neurological disorder, such as dystonia, hemiplegia, spasticity, epilepsy, myopathy, or muscular dystrophy.
        • Family history suggestive of a genetic etiology, including consanguinity.
        • Clinical or laboratory findings suggestive of an inborn error of metabolism.
        • Autism.
        • Severe neuropsychiatric condition, such as schizophrenia, bipolar disorder, Tourette syndrome, self-injurious behavior, or reverse sleep-wake cycles.
    • WES or WGS is requested by a board-certified geneticist or child neurologist.
    • Genetic counseling occurs before and after WES or WGS and is provided by a board-certified geneticist, genetic counselor, or child neurologist.
    • Submitted clinical documentation identifies ALL of the following

      • How WES/WGS will affect patient management.
      • Alternate etiologies have been considered and ruled out when possible, including environmental exposure, injury, or infection.
      • The rationale for requesting WES/WGS instead of a single-gene test or targeted gene panel.
      • Specialist consultation, including examination findings and family pedigree.
      • A pre-WES/WGS genetic counseling report addressing the approach to variants of unknown significance, a plan for addressing ACMG actionable genes, and the potential effect of results on other family members.

    Prenatal WES/WGS

    Prenatal WES or WGS is proven and medically necessary for diagnosis or evaluation of a suspected genetic disorder when all of the following criteria are met.

    ALL of the following

    • Chromosomal microarray analysis (CMA) and/or karyotyping has been performed and was uninformative.
    • WES/WGS is ordered by, or performed in consultation with, a medical geneticist or maternal-fetal medicine specialist (perinatologist).
    • The specimen is obtained from amniotic fluid, chorionic villi, fetal blood, or fetal tissue.
    • The fetus has ONE or more of the following clinical findings

      • Multiple congenital anomalies involving two or more distinct organ systems.

    Reanalysis of Previously Obtained Data

    Reanalysis of previously obtained uninformative WES or WGS data is medically necessary when the original WES/WGS eligibility criteria were met, including applicable qualifying clinical criteria, provider requirements, genetic counseling, and documentation requirements, and at least one of the following conditions is present.

    ALL of the following

    • Previously obtained WES or WGS data were uninformative.
    • ANY of the following reanalysis conditions

      • The individual experiences additional symptoms after the initial WES/WGS that cannot be explained by the results of the initial WES/WGS.
      • New data or new family history emerges that suggests a link between the individual's symptoms and specific genes.

    Due to insufficient evidence of efficacy, WES/WGS is unproven and not medically necessary for all other indications, including but not limited to evaluation of fetal demise; molecular profiling of tumors for the diagnosis, prognosis, or management of cancer; preimplantation genetic testing (PGT) in embryos; prenatal genetic diagnosis or screening; and screening or evaluating disorders in individuals who do not meet the coverage criteria.

    All other indications for fetal exome/genome testing are considered experimental, investigational, or unproven for evaluation of a fetus during pregnancy or a terminated fetus.

    WES/WGS is not medically necessary for evaluation of epilepsy when prior targeted epilepsy multigene panel testing has already identified a pathogenic or likely pathogenic variant that adequately explains the member's clinical presentation.

    Covered Indications

    Diagnostic WES/WGS for Members Diagnosed Before Age 21

    Covered for diagnostic evaluation when the member was diagnosed before age 21, meets one condition from A–D or at least two Section I-1E features, and all provider criteria are met.

    Diagnostic WES/WGS eligibility

    • Age at diagnosis: The member was diagnosed before age 21.Before age 21
    • Qualifying clinical pathway

      • One condition from A–D

        • A. Multiple congenital anomalies: Multiple congenital anomalies involving 2 or more organ systems.2 or more organ systems

    Eligibility Requirements

    A family history suggestive of a genetic etiology, including consanguinity, may count as one qualifying feature under the alternative eligibility pathway, which requires at least two qualifying features. For a fetal congenital anomaly limited to a single organ system, a suggestive family history is required for prenatal WES/WGS eligibility. New family history suggesting a link between the member’s symptoms and specific genes may also support reanalysis of previously uninformative WES/WGS data.

    For epilepsy, the member must have a documented history of at least two unprovoked seizures occurring more than 24 hours apart, with an unexplained etiology after standard evaluation. An epilepsy-specific multigene panel including at least 20 genes must either not have been performed or must have failed to identify a sufficient pathogenic or likely pathogenic variant, and previous WES/WGS must not have been completed.

    Coding and Operational Criteria

    Whole exome sequencing codesCPT
    81415Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis.
    81416Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (e.g., parents, siblings) (List separately in addition to code for primary procedure) (e.g. when both biological parents are to be tested then 81416 x2).
    81417Exome (e.g., unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained exome sequence (e.g., updated knowledge or unrelated condition/syndrome).
    Whole genome sequencing codesCPT
    81425Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis.
    81426Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure).
    81427Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
    Epilepsy seizure history
    Seizure historyAt least 2 unprovoked seizures occurring more than 24 hours apart
    Epilepsy etiologyUnexplained etiology, not attributable to structural, metabolic, infectious, immunologic, or acquired causes based on standard clinical evaluation
    Prior sequencingNo prior WES or WGS testing has been completed
    Epilepsy multigene panel
    Panel sizeAt least 20 genes
    Prior testing statusThe epilepsy-specific multigene panel has not been performed, or did not identify a pathogenic or likely pathogenic variant sufficient to explain the condition

    Provider Actions and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for WES and WGS. Submit authorization requests through Pres Online for Medicare, Medicaid, and Commercial members.

    • Pres Online: https://ds.phs.org/preslogin/index.jsp
    • Applies to Medicare, Medicaid, and Commercial members.
    Billing Rule

    WGS Code Authorization Status

    Authorization continues to be required for CPT 81427. Presbyterian is evaluating whether to adopt the external policy governing CPT 81425 and 81426 for ALOB.

    • CPT 81427: prior authorization continues to be required.

    Background

    Whole genome sequencing (WGS) examines the DNA sequence of the entire genome using high-throughput next-generation sequencing and bioinformatics. Whole exome sequencing (WES) examines the protein-coding portions of the genome—approximately 1% of the genome and about 20,000 genes. Both approaches are used to identify genetic variants associated with disorders; WGS may provide broader genomic assessment, while WES may have limitations in detecting copy-number variation, larger insertions or deletions, and GC-rich repeats.

    Definitions

    Whole genome sequencing (WGS)
    DefinitionSequencing the DNA sequence of the entire genome
    TechnologyUses high-throughput next-generation sequencing and sophisticated bioinformatics
    PurposeIdentifies variations associated with genetic disorders by comparison to a reference genome
    Whole exome sequencing (WES)
    DefinitionSequencing the protein-coding portions of the genome
    Genome coverageApproximately 1% of the entire genome
    Gene count

    Not Covered

    The following uses are not covered because WES/WGS is considered unproven or not medically necessary for these indications: molecular profiling of tumors for cancer diagnosis, prognosis, or management; preimplantation genetic testing in embryos; prenatal genetic diagnosis or screening; evaluation of fetal demise; and other fetal exome/genome testing during pregnancy or for a terminated fetus when the policy criteria are not met. Screening or evaluation of disorders when the stated coverage criteria are not met is also excluded.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyGenetic Testing: Standard Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS)
    Policy CodePolicy 7.12
    Change TypeAnnual review with material coverage updates
    Effective DateN/A
    Last ReviewMay 25, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for WES/WGS through Pres Online.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsCoding and Operational CriteriaProvider Actions and DocumentationBackgroundDefinitionsNot Covered
    A period of unexplained developmental regression unrelated to epilepsy or autism.
    Fetal hydrops of unknown etiology.
  1. A congenital anomaly involving a single organ system with a family history suggestive of a genetic etiology.
  2. B. Ongoing developmental regression: Unexplained, persistent loss of developmental milestones.
  3. C. Intellectual or developmental disability

    • Impaired intellectual function more than 2 standard deviations below the mean on standard cognitive assessment and impaired adaptive function.>2 standard deviations below mean
    • Impaired intellectual or physical function impacting adaptive skills.
  4. D. Epilepsy

    • Documented history of at least 2 unprovoked seizures occurring more than 24 hours apart.At least 2 unprovoked seizures >24 hours apart
    • Epilepsy is of unexplained etiology and cannot be attributed to a structural, metabolic, infectious, immunologic, traumatic, stroke-related, or other acquired cause based on standard clinical evaluation.
    • An epilepsy-specific multigene panel inclusive of at least 20 genes has not been performed, or did not identify a pathogenic or likely pathogenic variant sufficient to explain the epilepsy.Panel of at least 20 genes
    • Previous WES or WGS testing has not been completed.
  5. At least 2 Section I-1E features

    • Bilateral sensorineural hearing loss of unknown etiology.
    • Symptoms of a complex neurological disorder.
    • Family history suggestive of a genetic etiology, including consanguinity.
    • Clinical or laboratory findings suggestive of an inborn error of metabolism.
    • Autism.
    • Severe neuropsychiatric condition.
    • Unexplained developmental regression unrelated to epilepsy or autism.
  6. Ordering provider: WES or WGS is requested by a board-certified geneticist or child neurologist.
  7. Genetic counseling occurs before and after testing and is provided by a board-certified geneticist, genetic counselor, or child neurologist.
  8. Prenatal WES/WGS for Suspected Genetic Disorder

    Covered when all prenatal criteria are met.

    Prenatal WES/WGS

    • Suspected genetic disorder: WES/WGS is used for the diagnosis or evaluation of a suspected genetic disorder.
    • Uninformative prior testing: Chromosomal microarray analysis and/or karyotyping has been performed and was uninformative.
    • Specialist involvement: Testing is ordered by or in consultation with a medical geneticist or maternal-fetal medicine specialist (perinatologist).
    • Eligible fetal specimen: The specimen is obtained from amniotic fluid or chorionic villi, or DNA is extracted from fetal blood or fetal tissue.
    • Qualifying fetal anomaly or hydrops

      • Multiple congenital anomalies involving 2 or more distinct organ systems.2 or more organ systems
      • Fetal hydrops of unknown etiology.
      • A single-organ-system congenital anomaly with a family history suggestive of a genetic etiology.

    Reanalysis of Previously Obtained Uninformative WES/WGS Data

    Covered for previously obtained uninformative WES/WGS data when the initial testing criteria remain satisfied and at least one additional reanalysis condition is present.

    Reanalysis eligibility

    • Initial criteria remain satisfied: The applicable initial WES/WGS medical-necessity criteria are met.
    • Previously uninformative result: The previously obtained WES/WGS data were uninformative.
    • Additional basis for reanalysis

      • Additional unexplained symptoms: Additional symptoms developed after initial WES/WGS and cannot be explained by the initial results.
      • New data or family history: New data or new family history suggests a link between the individual’s symptoms and specific genes.
    Prior WES/WGSNo prior WES or WGS testing has been completed
    Age at diagnosis
    Age thresholdBefore age 21
    Applicable testingDiagnostic whole exome sequencing (WES) or whole genome sequencing (WGS)
    Clinical pathwayThe member must meet one qualifying condition from A-D or at least two qualifying features from E
    Section I-1E features
    Minimum featuresAt least 2 qualifying features
    Qualifying featuresBilateral sensorineural hearing loss of unknown etiology; symptoms of a complex neurological disorder; family history suggestive of a genetic etiology, including consanguinity; or findings suggestive of an inborn error of metabolism
    Additional qualifying featuresAutism; severe neuropsychiatric condition; or unexplained developmental regression unrelated to epilepsy or autism
  9. CPT 81425 and 81426: authorization requirements for ALOB remain under evaluation.
  10. CPT 81425 and 81426 are also listed in LBM AHS-G2063 for whole-genome sequencing of Mycobacterium spp. for drug-resistance detection.
  11. Documentation Required

    Prior Epilepsy Panel and Sequencing Requirements

    For epilepsy indications, an epilepsy-specific multigene panel including at least 20 genes must not have been performed, or must have been performed without identifying a pathogenic or likely pathogenic variant sufficient to explain the member’s epilepsy.

    • Document the prior epilepsy-panel result and whether it was explanatory.
    • Previous WES or WGS testing must not have been completed.
    Documentation Required

    Prior Prenatal Cytogenetic Testing

    Before prenatal WES or WGS, chromosomal microarray analysis (CMA) and/or karyotyping must have been performed and found to be uninformative.

    • Document the type of prenatal cytogenetic testing performed.
    • Include the result showing that CMA and/or karyotyping was uninformative.
    Documentation Required

    Clinical Rationale and Specialist Documentation

    Clinical documentation must explain how WES or WGS will affect patient management, address alternate etiologies considered and ruled out when possible, and explain why sequencing is requested instead of a single-gene test or targeted panel.

    • Include specialist consultation, examination findings, and family pedigree.
    • The request must be made by a board-certified geneticist or child neurologist; prenatal testing must be ordered by or performed in consultation with a medical geneticist or maternal-fetal medicine specialist.
    Documentation Required

    Genetic Counseling Report

    The pre-WES/WGS genetic counseling report must address the approach to variants of unknown significance and the plan for addressing ACMG actionable genes. It should also discuss potential effects of results on other family members.

    • Genetic counseling is required before and after WES/WGS.
    • Counseling must be provided by a board-certified geneticist, genetic counselor, or child neurologist.
    Documentation Required

    Prenatal and Reanalysis Documentation

    For prenatal testing and reanalysis, document the required prior testing and supporting clinical information. The record should identify the ordering or consulting specialist and the specimen source, and for reanalysis should explain the new symptoms, data, or family history supporting the request.

    • Prenatal specimen must be from amniotic fluid, chorionic villi, fetal blood, or fetal tissue.
    • Reanalysis requires previously obtained uninformative WES/WGS data and either additional unexplained symptoms or new data or family history suggesting a gene-related explanation.
    Denial Risk

    Indications Outside Covered Criteria

    WES/WGS is unproven and not medically necessary for indications outside the covered criteria. This includes fetal demise, tumor molecular profiling, preimplantation genetic testing, prenatal genetic diagnosis or screening, and screening or evaluation when the stated criteria are not met.

    • All other fetal exome/genome testing during pregnancy or after termination is considered experimental, investigational, or unproven.
    Denial Risk

    Explanatory Prior Epilepsy Result

    WES/WGS is not medically necessary for epilepsy when a prior targeted epilepsy multigene panel has identified a pathogenic or likely pathogenic variant that adequately explains the member’s clinical presentation.

    • Document the prior panel result and its relationship to the member’s epilepsy.
    Denial Risk

    Eligibility or Prior-Testing Failure

    Requests may be denied when eligibility, clinical findings, prior-testing, or other medical-necessity requirements are not met. For non-prenatal indications, the member must generally have been diagnosed before age 21 and meet the applicable clinical criteria.

    • Confirm required clinical findings and the applicable epilepsy criteria.
    • Confirm that required prior testing has not been completed or was non-explanatory.
    • Document the ordering or consulting specialist and all required supporting information.
    Documentation Required

    Provider Actions: Genetic Counseling

    Arrange genetic counseling before and after WES/WGS. Counseling must be provided by a board-certified geneticist, genetic counselor, or child neurologist and must address variants of unknown significance and ACMG actionable findings.

    • Ensure counseling documentation is included in the clinical record.
    • Discuss potential effects of results on other family members.
    Prior Authorization

    Provider Actions: Ordering and Consultation

    Ensure diagnostic WES/WGS is requested by a board-certified geneticist or child neurologist. For prenatal WES/WGS, order the test directly or consult with a medical geneticist or maternal-fetal medicine specialist, and submit the clinical findings, prior testing, specimen source, and management rationale.

    • Verify prior authorization through Pres Online before testing.
    • Document examination findings, family pedigree, alternate etiologies, and why WES/WGS is preferred over a single-gene test or targeted panel.
    Approximately 20,000 genes
    Reanalysis
    DefinitionAdditional analysis of previously obtained uninformative WES/WGS data
    Initial criteriaThe policy’s initial WES/WGS criteria must remain satisfied
    Reanalysis supportAdditional unexplained symptoms, or new data or family history suggesting a link between symptoms and specific genes, must support review